insights_auto
Outlook: 57.1% bullish·0.0% bearish
Go to analysischevron_right
BIIB:NASDAQ
Biogen Inc
$240.98
arrow_downward
-0.87%(-2.12) 1D
$240.98
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 21, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB...
Open
$242.02
High
$243.32
Low
$240.13
Mkt. cap
35.61B
Avg. vol.
1.19M
Volume
0.00
P/E ratio
42.68
52-wk high
$244.65
52-wk low
$138.00
EPS
$5.65
Beta
0.09
Shares outstanding
147.75M
No. of employees
8K
Open
$242.02
High
$243.32
Low
$240.13
Mkt. cap
35.61B
Avg. vol.
1.19M
Volume
0.00
P/E ratio
42.68
52-wk high
$244.65
52-wk low
$138.00
EPS
$5.65
Beta
0.09
Shares outstanding
147.75M
No. of employees
8K
News stories
From web sources and news partners
GuruFocus
·
15 hours ago
BIIB Maintained by TD Cowen -- Price Target Raised to $250
Seeking Alpha
·
16 hours ago
Biogen Q3 Earnings Preview: Grounds For Optimism, But Disappointment The Norm
Investing.com
·
17 hours ago
Biogen shares may move 4.3% on Oct. 28 earnings release
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc
CEOChris Viehbacher
Employees7.5K
Founded1978
HeadquartersCambridge, Massachusetts, United States
SectorBiotechnology
Websitebiogen.com